Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Lorin Stein

Nurse Practitioner, Acute Care Charleston, SC Nurse Practitioner

NPI 1902292261 CMS profile 10911630

1938 Charlie Hall Blvd Unit B, Charleston, SC 29414

Open in the dashboard

General payments

$4,980

237 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lorin Stein of Charleston, SC is reported in the CMS Open Payments database as having received $4,980 across 237 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Nurse Practitioner, Acute Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,124 43
2024 General $1,081 49
2023 General $1,016 43
2022 General $714 40
2021 General $1,045 62

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lorin Stein
  • Nurse Practitioner, Acute Care median
  • Middle half of Nurse Practitioner, Acute Care
  • National median

In program year 2025, general payments to Lorin Stein were reported at $1,124. Among 11,827 Nurse Practitioner, Acute Care profiles paid that year, the median was $152 and the middle half received between $48 and $458.

Show as a table
Year Lorin Stein Nurse Practitioner, Acute Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,045 $123 $38–$327 $132
2022 $714 $130 $44–$369 $149
2023 $1,016 $144 $49–$410 $160
2024 $1,081 $146 $48–$433 $164
2025 $1,124 $152 $48–$458 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. ViiV Healthcare Company $942 55 payments
  2. Insmed, Inc. $792 28 payments
  3. Gilead Sciences, Inc. $475 19 payments
  4. Melinta Therapeutics, Inc. $469 22 payments
  5. AbbVie, Inc. $419 28 payments
  6. Astellas Pharma US Inc $404 13 payments
  7. Shionogi Inc $300 10 payments
  8. Merck Sharp & Dohme Corporation $260 16 payments
  9. Paratek Pharmaceuticals, Inc. $184 11 payments
  10. Janssen Biotech, Inc. $167 12 payments
  11. Other $567 23 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,780 234 payments
  2. Education $200 3 payments
Products named General payments · program years 2021–2025
  1. Arikayce $792 28 payments
  2. DOVATO $380 19 payments
  3. Kimyrsa $372 18 payments
  4. CABENUVA $324 23 payments
  5. Vabomere $317 15 payments
  6. Fetroja $300 10 payments
  7. DALVANCE $258 16 payments
  8. Rezzayo $255 12 payments
  9. SYMTUZA $232 13 payments
  10. NUZYRA $184 11 payments
  11. Other $2,116 114 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

431

Median for Nurse Practitioner: 389

Drug cost

$336,273

Median for Nurse Practitioner: $21,885

Branded share of claims

34.8%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Biktarvy Bictegrav/Emtricit/Tenofov Ala Brand 53 $212,626
Symtuza Darunavir/Cob/Emtri/Tenof Alaf Brand 13 $60,213
Triumeq Abacavir/Dolutegravir/Lamivudi Brand 11 $40,700
Daptomycin Generic 19 $8,703
Ceftriaxone Ceftriaxone Sodium Brand 30 $3,183
Cefepime Hcl Generic 18 $2,690
Vancomycin Hcl Generic 18 $2,530
Doxycycline Hyclate Generic 46 $1,097
Ritonavir Generic 11 $781
Cephalexin Generic 36 $594

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$106,963

Of which drugs: $48,758

Medicare patients

298

Average age 76

Services billed

39,719

145 women, 153 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 66%
Chronic kidney disease 45%
Diabetes 43%
Depression 42%
Ischemic heart disease 40%
Heart failure 39%
Atrial fibrillation 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Arikayce
  • Insmed, Inc. $156
$156 — —
CABENUVA
  • ViiV Healthcare Company $114
$114 — —
Fetroja
  • Shionogi Inc $89
$89 — —
Cresemba
  • Astellas Pharma US Inc $73
$73 — —
Rezzayo
  • Melinta Therapeutics, Inc. $48
$48 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

237 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Acute Care in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record